Lluis M Mir Selected Research

Norisoprenoids (Irones)

10/2017	Gallein, a Gβγ subunit signalling inhibitor, inhibits metastatic spread of tumour cells expressing OR51E2 and exposed to its odorant ligand.
1/2017	Structurally related odorant ligands of the olfactory receptor OR51E2 differentially promote metastasis emergence and tumor growth.
1/2014	Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lluis M Mir Research Topics

Disease

24	Neoplasms (Cancer) 01/2020 - 10/2003
6	Neoplasm Metastasis (Metastasis) 10/2017 - 12/2006
5	Melanoma (Melanoma, Malignant) 11/2017 - 04/2009
2	Prostatic Neoplasms (Prostate Cancer) 10/2017 - 01/2014
1	Neuroblastoma 01/2022
1	Wounds and Injuries (Trauma) 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2014
1	Colonic Neoplasms (Colon Cancer) 01/2014
1	Fever (Fevers) 09/2013
1	Ductal Carcinoma 09/2012
1	Experimental Melanoma 08/2011
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2011
1	Hyperthermia 04/2008
1	Hypoxia (Hypoxemia) 12/2006
1	Carcinoma (Carcinomatosis) 12/2003

Drug/Important Bio-Agent (IBA)

7	Pharmaceutical PreparationsIBA 01/2016 - 10/2003
5	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020 - 10/2003
3	Norisoprenoids (Irones)IBA 10/2017 - 01/2014
3	Odorant Receptors (Odorant Receptor)IBA 10/2017 - 01/2014
3	LigandsIBA 01/2017 - 09/2008
3	Cisplatin (Platino)FDA LinkGeneric 09/2012 - 12/2003
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 09/2013
2	AntigensIBA 01/2014 - 09/2008
2	VaccinesIBA 01/2014 - 01/2014
2	Proteins (Proteins, Gene)FDA Link 08/2011 - 12/2006
1	Biological ProductsIBA 01/2022
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021
1	Biocompatible Materials (Biomaterials)IBA 01/2021
1	Chemokine ReceptorsIBA 11/2017
1	Chimeric Antigen ReceptorsIBA 11/2017
1	galleinIBA 10/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Immune Checkpoint InhibitorsIBA 01/2016
1	CytokinesIBA 01/2016
1	CalreticulinIBA 01/2014
1	Adenosine Triphosphate (ATP)IBA 01/2014
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2014
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2014
1	HMGB1 Protein (HMG1)IBA 01/2014
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2014
1	ORALIT (ORS)IBA 01/2014
1	DNA VaccinesIBA 01/2014
1	1-aminomethylphosphonic acidIBA 09/2013
1	Peptides (Polypeptides)IBA 09/2013
1	C-Reactive ProteinIBA 09/2013
1	type IV collagen alpha3 chain (Goodpasture antigen)IBA 03/2013
1	Cobalt-60IBA 09/2012
1	LuciferasesIBA 08/2011
1	IntegrinsIBA 08/2011
1	DisintegrinsIBA 08/2011
1	Thrombospondin 1IBA 08/2011
1	Protein Isoforms (Isoforms)IBA 08/2011
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2011
1	CaveolinsIBA 04/2009
1	lucifer yellowIBA 04/2009
1	ClathrinIBA 04/2009
1	Interferon-gamma (Interferon, gamma)IBA 09/2008
1	CPG-oligonucleotideIBA 09/2008
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 09/2008
1	Toll-Like Receptors (Toll-Like Receptor)IBA 09/2008
1	OligodeoxyribonucleotidesIBA 09/2008
1	Interferon-alpha (Interferon Alfa)IBA 04/2008
1	AngiopoietinsIBA 12/2006
1	ElementsIBA 08/2005

Therapy/Procedure

5	Therapeutics 01/2020 - 09/2008
3	Electrodes (Electrode) 11/2008 - 11/2007
2	Immunotherapy 11/2017 - 01/2016
2	Radiotherapy 09/2012 - 04/2008
2	Drug Therapy (Chemotherapy) 04/2008 - 02/2007
1	Intraperitoneal Injections 10/2017
1	Palliative Care (Palliative Therapy) 01/2016
1	Aftercare (After-Treatment) 08/2011
1	Heterologous Transplantation (Xenotransplantation) 01/2011